Provider: NIHR Journals Library Content:text/plain; charset="UTF-8" TY - JOUR LB - 1. AU - Merlin, T AU - Lehman, S AU - Hiller, J AU - Ryan, P TI - The ‘linked evidence approach’ to assess medical tests: a critical analysis J2 - Int J Technol Assess Health Care PY - 2013 VL - 29 SP - 343 EP - 350 UR - http://dx.doi.org/10.1017/S0266462313000287 ER - TY - BOOK LB - 2. AU - NICE TI - Crohn’s Disease: Management in Adults, Children and Young People CY - London PB - NICE PY - 2012 UR - www.nice.org.uk/guidance/cg152 Y2 - 6 October 2014 ER - TY - JOUR LB - 3. AU - Clark, W AU - Raftery, J AU - Song, F AU - Barton, P AU - Cummins, C AU - Fry-Smith, A TI - Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease J2 - Health Technol Assess PY - 2003 VL - 7 IS - 3 UR - http://dx.doi.org/10.3310/hta7030 ER - TY - ELEC LB - 4. AU - NHS Choices TI - Crohn’s Disease PY - 2013 UR - www.nhs.uk/Conditions/Crohns-disease/Pages/Introduction.aspx M1 - 6 October 2014 ER - TY - JOUR LB - 5. AU - Dretzke, J AU - Edlin, R AU - Round, J AU - Connock, M AU - Hulme, C AU - Czeczot, J TI - A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease J2 - Health Technol Assess PY - 2011 VL - 15 IS - 6 UR - http://dx.doi.org/10.3310/hta15060 ER - TY - BOOK LB - 6. AU - NICE TI - Infliximab (Review) and Adalimumab for the Treatment of Crohn’s Disease CY - London PB - NICE PY - 2010 UR - www.nice.org.uk/guidance/TA187 Y2 - 6 October 2014 ER - TY - JOUR LB - 7. AU - Hanauer, SB AU - Sandborn, W TI - Management of Crohn’s disease in adults J2 - Am J Gastroenterol PY - 2001 VL - 96 SP - 635 EP - 643 UR - http://dx.doi.org/10.1111/j.1572-0241.2001.03671.x ER - TY - JOUR LB - 8. AU - Jenkins, HR TI - Inflammatory bowel disease J2 - Arch Dis Child PY - 2001 VL - 85 SP - 435 EP - 437 UR - http://dx.doi.org/10.1136/adc.85.5.435 ER - TY - JOUR LB - 9. AU - Sostegni, R AU - Daperno, M AU - Scaglione, N AU - Lavagna, A AU - Rocca, R AU - Pera, A TI - Review article: Crohn’s disease: monitoring disease activity J2 - Aliment Pharmacol Ther PY - 2003 VL - 17 IS - Suppl. 2 SP - 11 EP - 17 UR - http://dx.doi.org/10.1046/j.1365-2036.17.s2.17.x ER - TY - JOUR LB - 10. AU - Hyams, J AU - Crandall, W AU - Kugathasan, S AU - Griffiths, A AU - Olson, A AU - Johanns, J TI - Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children J2 - Gastroenterology PY - 2007 VL - 132 SP - 863 EP - 873 UR - http://dx.doi.org/10.1053/j.gastro.2006.12.003 ER - TY - JOUR LB - 11. AU - Vermeire, S AU - Van Assche, G AU - Rutgeerts, P TI - Laboratory markers in IBD: useful, magic, or unnecessary toys? J2 - Gut PY - 2006 VL - 55 SP - 426 EP - 431 UR - http://dx.doi.org/10.1136/gut.2005.069476 ER - TY - JOUR LB - 12. AU - Sandborn, WJ AU - Feagan, BG AU - Hanauer, SB AU - Lochs, H AU - Lofberg, R AU - Modigliani, R TI - A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease J2 - Gastroenterology PY - 2002 VL - 122 SP - 512 EP - 530 UR - http://dx.doi.org/10.1053/gast.2002.31072 ER - TY - JOUR LB - 13. AU - Irvine, EJ TI - Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group J2 - J Clin Gastroenterol PY - 1995 VL - 20 SP - 27 EP - 32 UR - http://dx.doi.org/10.1097/00004836-199501000-00008 ER - TY - JOUR LB - 14. AU - Allez, M AU - Karmiris, K AU - Louis, E AU - Van Assche, G AU - Ben-Horin, S AU - Klein, A TI - Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects J2 - J Crohns Colitis PY - 2010 VL - 4 SP - 355 EP - 366 UR - http://dx.doi.org/10.1016/j.crohns.2010.04.004 ER - TY - BOOK LB - 15. AU - Freeman, K AU - Connock, M AU - Mistry, H AU - Taylor-Phillips, S AU - Court, R AU - Tsertsvadze, A TI - Crohn’s Disease: Tests for Therapeutic Monitoring of TNF Inhibitors (LISA-TRACKER ELISA kits, TNFα-Blocker ELISA kits, and Promonitor ELISA kits): Final Protocol CY - London PB - NICE PY - 2014 UR - www.nice.org.uk/guidance/gid-dt24/documents/crohns-disease-tests-for-therapeutic-monitoring-of-tnf-inhibitors-lisatracker-elisa-kits-tnfablocker-elisa-kits-and-promonitor-elisa-kits-final-protocol2 Y2 - 21 April 2015 ER - TY - JOUR LB - 16. AU - Lichtenstein, GR AU - Hanauer, SB AU - Sandborn, WJ TI - Management of Crohn’s disease in adults J2 - Am J Gastroenterol PY - 2009 VL - 104 SP - 465 EP - 483 UR - http://dx.doi.org/10.1038/ajg.2008.168 ER - TY - JOUR LB - 17. AU - Dignass, A AU - Van Assche, G AU - Lindsay, JO AU - Lemann, M AU - Soderholm, J AU - Colombel, JF TI - The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management J2 - J Crohns Colitis PY - 2010 VL - 4 SP - 28 EP - 62 UR - http://dx.doi.org/10.1016/j.crohns.2009.12.002 ER - TY - BOOK LB - 18. AU - Joint Formulary Committee TI - British National Formulary CY - London PB - BMJ Group and Pharmaceutical Press UR - www.medicinescomplete.com Y2 - 6 October 2014 ER - TY - BOOK LB - 19. AU - Joint Formulary Committee TI - British National Formulary for Children CY - London PB - BMJ Group and Pharmaceutical Press UR - www.medicinescomplete.com Y2 - 6 October 2014 ER - TY - JOUR LB - 20. AU - Gregor, JC AU - McDonald, JW AU - Klar, N AU - Wall, R AU - Atkinson, K AU - Lamba, B TI - An evaluation of utility measurement in Crohn’s disease J2 - Inflamm Bowel Dis PY - 1997 VL - 3 SP - 265 EP - 276 UR - http://dx.doi.org/10.1002/ibd.3780030405 ER - TY - JOUR LB - 21. AU - Cohen, RD TI - The quality of life in patients with Crohn’s disease J2 - Aliment Pharmacol Ther PY - 2002 VL - 16 SP - 1603 EP - 1609 UR - http://dx.doi.org/10.1046/j.1365-2036.2002.01323.x ER - TY - ELEC LB - 22. AU - IBD Standards Group TI - Standards for the Healthcare of People who have Inflammatory Bowel Disease (IBD): 2013 Update PY - 2013 UR - www.ibdstandards.org.uk/uploaded_files/IBDstandards.pdf M1 - 25 February 2015 ER - TY - JOUR LB - 23. AU - Bassi, A AU - Dodd, S AU - Williamson, P AU - Bodger, K TI - Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study J2 - Gut PY - 2004 VL - 53 SP - 1471 EP - 1478 UR - http://dx.doi.org/10.1136/gut.2004.041616 ER - TY - JOUR LB - 24. AU - Jewell, DP AU - Satsangi, J AU - Lobo, A AU - Probert, C AU - Forbes, A AU - Ghosh, S TI - Infliximab use in Crohn’s disease: impact on health care resources in the UK J2 - Eur J Gastroenterol Hepatol PY - 2005 VL - 17 SP - 1047 EP - 1052 UR - http://dx.doi.org/10.1097/00042737-200510000-00007 ER - TY - JOUR LB - 25. AU - Sprakes, MB AU - Ford, AC AU - Suares, NC AU - Warren, L AU - Greer, D AU - Donnellan, CF TI - Costs of care for Crohn’s disease following the introduction of infliximab: a single-centre UK experience J2 - Aliment Pharmacol Ther PY - 2010 VL - 32 SP - 1357 EP - 1363 UR - http://dx.doi.org/10.1111/j.1365-2036.2010.04482.x ER - TY - JOUR LB - 26. AU - Buchanan, J AU - Wordsworth, S AU - Ahmad, T AU - Perrin, A AU - Vermeire, S AU - Sans, M TI - Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers J2 - J Crohns Colitis PY - 2011 VL - 5 SP - 301 EP - 316 UR - http://dx.doi.org/10.1016/j.crohns.2011.02.005 ER - TY - JOUR LB - 27. AU - Hanauer, SB AU - Feagan, BG AU - Lichtenstein, GR AU - Mayer, LF AU - Schreiber, S AU - Colombel, JF TI - Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial J2 - Lancet PY - 2002 VL - 359 SP - 1541 EP - 1549 UR - http://dx.doi.org/10.1016/S0140-6736(02)08512-4 ER - TY - JOUR LB - 28. AU - Sands, BE AU - Blank, MA AU - Patel, K AU - van Deventer, SJ AU - ACCENT II Study TI - Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study J2 - Clin Gastroenterol Hepatol PY - 2004 VL - 2 SP - 912 EP - 920 UR - http://dx.doi.org/10.1016/S1542-3565(04)00414-8 ER - TY - JOUR LB - 29. AU - Colombel, JF AU - Sandborn, WJ AU - Rutgeerts, P AU - Enns, R AU - Hanauer, SB AU - Panaccione, R TI - Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial J2 - Gastroenterology PY - 2007 VL - 132 SP - 52 EP - 65 UR - http://dx.doi.org/10.1053/j.gastro.2006.11.041 ER - TY - JOUR LB - 30. AU - Ben-Horin, S AU - Chowers, Y TI - Tailoring anti-TNF therapy in IBD: drug levels and disease activity J2 - Nat Rev Gastroenterol Hepatol PY - 2014 VL - 11 SP - 243 EP - 255 UR - http://dx.doi.org/10.1038/nrgastro.2013.253 ER - TY - JOUR LB - 31. AU - Targan, SR AU - Hanauer, SB AU - van Deventer, SJ AU - Mayer, L AU - Present, DH AU - Braakman, T TI - A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group J2 - N Engl J Med PY - 1997 VL - 337 SP - 1029 EP - 1035 UR - http://dx.doi.org/10.1056/NEJM199710093371502 ER - TY - JOUR LB - 32. AU - Hanauer, SB AU - Sandborn, WJ AU - Rutgeerts, P AU - Fedorak, RN AU - Lukas, M AU - MacIntosh, D TI - Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial J2 - Gastroenterology PY - 2006 VL - 130 SP - 323 EP - 333 UR - http://dx.doi.org/10.1053/j.gastro.2005.11.030 ER - TY - JOUR LB - 33. AU - de Boer, N AU - Lowenberg, M AU - Hoentjen, F TI - Management of Crohn’s disease in poor responders to adalimumab J2 - Clin Exp Gastroenterol PY - 2014 VL - 7 SP - 83 EP - 92 ER - TY - JOUR LB - 34. AU - Bendtzen, K TI - Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine J2 - Immunotherapy PY - 2012 VL - 4 SP - 1167 EP - 1179 UR - http://dx.doi.org/10.2217/imt.12.114 ER - TY - JOUR LB - 35. AU - Gisbert, JP AU - Panes, J TI - Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review J2 - Am J Gastroenterol PY - 2009 VL - 104 SP - 760 EP - 767 UR - http://dx.doi.org/10.1038/ajg.2008.88 ER - TY - JOUR LB - 36. AU - Billioud, V AU - Sandborn, WJ AU - Peyrin-Biroulet, L TI - Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review J2 - Am J Gastroenterol PY - 2011 VL - 106 SP - 674 EP - 684 UR - http://dx.doi.org/10.1038/ajg.2011.60 ER - TY - JOUR LB - 37. AU - Carrillo-Ramos, MJ AU - Duarte-Chang, C AU - Maldonado-Perez, B AU - Beltran-Castano, R AU - Castro-Laria, L AU - Arguelles-Arias, F TI - Adalimumab or infliximab for the treatment of inflammatory bowel disease patients: which is more effective? J2 - Gastroenterology PY - 2014 VL - 146 SP - S-196 UR - http://dx.doi.org/10.1016/S0016-5085(14)60690-9 ER - TY - JOUR LB - 38. AU - Maser, EA AU - Villela, R AU - Silverberg, MS AU - Greenberg, GR TI - Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease J2 - Clin Gastroenterol Hepatol PY - 2006 VL - 4 SP - 1248 EP - 1254 UR - http://dx.doi.org/10.1016/j.cgh.2006.06.025 ER - TY - JOUR LB - 39. AU - Cassinotti, A AU - Travis, S TI - Why don’t we just measure infliximab drug levels in IBD? J2 - Pract Gastroenterol PY - 2010 VL - 34 SP - 11 EP - 20 ER - TY - JOUR LB - 40. AU - Hanauer, SB AU - Wagner, CL AU - Bala, M AU - Mayer, L AU - Travers, S AU - Diamond, RH TI - Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease J2 - Clin Gastroenterol Hepatol PY - 2004 VL - 2 SP - 542 EP - 553 UR - http://dx.doi.org/10.1016/S1542-3565(04)00238-1 ER - TY - JOUR LB - 41. AU - Ungar, B AU - Kopylov, U AU - Yavzori, M AU - Fudim, E AU - Picard, O AU - Lahat, A TI - Predictors of formation of antibodies to infliximab (ATI) and secondary loss of response in IBD patients treated with infliximab J2 - J Crohns Colitis PY - 2014 VL - 8 SP - S45 UR - http://dx.doi.org/10.1016/S1873-9946(14)60087-8 ER - TY - JOUR LB - 42. AU - Barry, D AU - Bloomfeld, RS TI - The prevalence of human antichimeric antibodies in patients on infliximab increases with age J2 - Gastroenterology PY - 2012 VL - 142 SP - S-387 UR - http://dx.doi.org/10.1016/s0016-5085(12)61466-8 ER - TY - JOUR LB - 43. AU - Baert, F AU - Noman, M AU - Vermeire, S AU - Van Assche, G AU - D’ Haens, G AU - Carbonez, A TI - Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease J2 - N Engl J Med PY - 2003 VL - 348 SP - 601 EP - 608 UR - http://dx.doi.org/10.1056/NEJMoa020888 ER - TY - JOUR LB - 44. AU - Khanna, R AU - Sattin, BD AU - Afif, W AU - Benchimol, EI AU - Bernard, EJ AU - Bitton, A TI - Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease J2 - Aliment Pharmacol Ther PY - 2013 VL - 38 SP - 447 EP - 459 UR - http://dx.doi.org/10.1111/apt.12407 ER - TY - JOUR LB - 45. AU - Vermeire, S AU - Noman, M AU - Van Assche, G AU - Baert, F AU - D’Haens, G AU - Rutgeerts, P TI - Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease J2 - Gut PY - 2007 VL - 56 SP - 1226 EP - 1231 UR - http://dx.doi.org/10.1136/gut.2006.099978 ER - TY - JOUR LB - 46. AU - Vande Casteele, N AU - Cuypers, L AU - Singh, S AU - Hauenstein, S AU - Ohrmund, L AU - Chuang, E TI - Transient versus sustained antibodies to infliximab: possibility to overcome low titer antibody responses by dose optimisation J2 - J Crohns Colitis PY - 2012 VL - 6 SP - S110 UR - http://dx.doi.org/10.1016/S1873-9946(12)60273-6 ER - TY - JOUR LB - 47. AU - Ainsworth, MA AU - Bendtzen, K AU - Brynskov, J TI - Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease J2 - Am J Gastroenterol PY - 2008 VL - 103 SP - 944 EP - 948 UR - http://dx.doi.org/10.1111/j.1572-0241.2007.01638.x ER - TY - JOUR LB - 48. AU - Karmiris, K AU - Paintaud, G AU - Noman, M AU - Magdelaine-Beuzelin, C AU - Ferrante, M AU - Degenne, D TI - Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease J2 - Gastroenterology PY - 2009 VL - 137 SP - 1628 EP - 1640 UR - http://dx.doi.org/10.1053/j.gastro.2009.07.062 ER - TY - JOUR LB - 49. AU - Garces, S AU - Demengeot, J AU - Benito-Garcia, E TI - The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis J2 - Ann Rheum Dis PY - 2013 VL - 72 SP - 1947 EP - 1955 UR - http://dx.doi.org/10.1136/annrheumdis-2012-202220 ER - TY - JOUR LB - 50. AU - Gils, A AU - Vande Casteele, N AU - Poppe, R AU - Van de Wouwer, M AU - Compernolle, G AU - Peeters, M TI - Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization J2 - Ther Drug Monit PY - 2014 VL - 36 SP - 669 EP - 673 UR - http://dx.doi.org/10.1097/FTD.0000000000000074 ER - TY - JOUR LB - 51. AU - van Schie, KA AU - Hart, MH AU - de Groot, ER AU - Kruithof, S AU - Aarden, LA AU - Wolbink, GJ TI - The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region J2 - Ann Rheum Dis PY - 2015 VL - 74 SP - 311 EP - 314 UR - http://dx.doi.org/10.1136/annrheumdis-2014-206237 ER - TY - JOUR LB - 52. AU - Steenholdt, C AU - Palarasah, Y AU - Bendtzen, K AU - Teisner, A AU - Brynskov, J AU - Teisner, B TI - Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease J2 - Aliment Pharmacol Ther PY - 2013 VL - 37 SP - 1172 EP - 1183 UR - http://dx.doi.org/10.1111/apt.12330 ER - TY - JOUR LB - 53. AU - Van Assche, G AU - Magdelaine-Beuzelin, C AU - D’Haens, G AU - Baert, F AU - Noman, M AU - Vermeire, S TI - Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial J2 - Gastroenterology PY - 2008 VL - 134 SP - 1861 EP - 1868 UR - http://dx.doi.org/10.1053/j.gastro.2008.03.004 ER - TY - JOUR LB - 54. AU - Feagan, BG AU - McDonald, JW AU - Panaccione, R AU - Enns, RA AU - Bernstein, CN AU - Ponich, TP TI - Methotrexate for the prevention of antibodies to infliximab in patients with Crohn’s disease J2 - Gastroenterology PY - 2010 VL - 138 SP - S167 EP - S168 UR - http://dx.doi.org/10.1016/S0016-5085(10)60767-6 ER - TY - JOUR LB - 55. AU - Colombel, JF AU - Sandborn, WJ AU - Reinisch, W AU - Mantzaris, GJ AU - Kornbluth, A AU - Rachmilewitz, D TI - Infliximab, azathioprine, or combination therapy for Crohn’s disease J2 - N Engl J Med PY - 2010 VL - 362 SP - 1383 EP - 1395 UR - http://dx.doi.org/10.1056/NEJMoa0904492 ER - TY - JOUR LB - 56. AU - Afif, W AU - Loftus, EV AU - Faubion, WA, Jr AU - Kane, SV AU - Bruining, DH AU - Hanson, KA TI - Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease J2 - Am J Gastroenterol PY - 2010 VL - 105 SP - 1133 EP - 1139 UR - http://dx.doi.org/10.1038/ajg.2010.9 ER - TY - JOUR LB - 57. AU - Roblin, X AU - Rinaudo, M AU - Del Tedesco, E AU - Phelip, JM AU - Genin, C AU - Peyrin-Biroulet, L TI - Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases J2 - Am J Gastroenterol PY - 2014 VL - 109 SP - 1250 EP - 1256 UR - http://dx.doi.org/10.1038/ajg.2014.146 ER - TY - JOUR LB - 58. AU - Paul, S AU - Del Tedesco, E AU - Marotte, H AU - Rinaudo-Gaujous, M AU - Moreau, A AU - Phelip, JM TI - Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study J2 - Inflamm Bowel Dis PY - 2013 VL - 19 SP - 2568 EP - 2576 UR - http://dx.doi.org/10.1097/MIB.0b013e3182a77b41 ER - TY - JOUR LB - 59. AU - Pariente, B AU - Pineton de Chambrun, G AU - Krzysiek, R AU - Desroches, M AU - Louis, G AU - De Cassan, C TI - Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease J2 - Inflamm Bowel Dis PY - 2012 VL - 18 SP - 1199 EP - 1206 UR - http://dx.doi.org/10.1002/ibd.21839 ER - TY - JOUR LB - 60. AU - Steenholdt, C TI - Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn’s disease J2 - Dan Med J PY - 2013 VL - 60 SP - B4616 ER - TY - JOUR LB - 61. AU - Ben-Horin, S AU - Chowers, Y TI - Review article: loss of response to anti-TNF treatments in Crohn’s disease J2 - Aliment Pharmacol Ther PY - 2011 VL - 33 SP - 987 EP - 995 UR - http://dx.doi.org/10.1111/j.1365-2036.2011.04612.x ER - TY - JOUR LB - 62. AU - Cassinotti, A AU - Travis, S TI - Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review J2 - Inflamm Bowel Dis PY - 2009 VL - 15 SP - 1264 EP - 1275 UR - http://dx.doi.org/10.1002/ibd.20899 ER - TY - JOUR LB - 63. AU - Lee, LY AU - Sanderson, JD AU - Irving, PM TI - Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis J2 - Eur J Gastroenterol Hepatol PY - 2012 VL - 24 SP - 1078 EP - 1085 UR - http://dx.doi.org/10.1097/MEG.0b013e32835558cf ER - TY - JOUR LB - 64. AU - Chaparro, M AU - Guerra, I AU - Munoz-Linares, P AU - Gisbert, JP TI - Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease J2 - Aliment Pharmacol Ther PY - 2012 VL - 35 SP - 971 EP - 986 UR - http://dx.doi.org/10.1111/j.1365-2036.2012.05057.x ER - TY - JOUR LB - 65. AU - Vande Casteele, N AU - Gils, A AU - Ballet, V AU - Compernolle, G AU - Peeters, M AU - Van Steen, K TI - Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT Study (OP001) J2 - United Europ Gastroenterol J PY - 2013 VL - 1 SP - A1 ER - TY - JOUR LB - 66. AU - Scott, FI AU - Lichtenstein, GR TI - Therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease J2 - Curr Treat Options Gastroenterol PY - 2014 VL - 12 SP - 59 EP - 75 UR - http://dx.doi.org/10.1007/s11938-013-0004-5 ER - TY - JOUR LB - 67. AU - Vande Casteele, N AU - Buurman, DJ AU - Sturkenboom, MG AU - Kleibeuker, JH AU - Vermeire, S AU - Rispens, T TI - Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays J2 - Aliment Pharmacol Ther PY - 2012 VL - 36 SP - 765 EP - 771 UR - http://dx.doi.org/10.1111/apt.12030 ER - TY - JOUR LB - 68. AU - Moher, D AU - Liberati, A AU - Tetzlaff, J AU - Altman, DG AU - The PRISMA Group TI - Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement J2 - BMJ PY - 2009 VL - 339 SP - b2535 UR - http://dx.doi.org/10.1136/bmj.b2535 ER - TY - JOUR LB - 69. AU - Whiting, PF AU - Rutjes, AWS AU - Westwood, ME AU - Mallett, S AU - Deeks, JJ AU - Reitsma, JB TI - QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies J2 - Ann Intern Med PY - 2011 VL - 155 SP - 529 EP - 536 UR - http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009 ER - TY - JOUR LB - 70. AU - Higgins, JP AU - Altman, DG AU - Gotzsche, PC AU - Juni, P AU - Moher, D AU - Oxman, AD TI - The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials J2 - BMJ PY - 2011 VL - 343 UR - http://dx.doi.org/10.1136/bmj.d5928 ER - TY - JOUR LB - 71. AU - Downs, SH AU - Black, N TI - The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions J2 - J Epidemiol Community Health PY - 1998 VL - 52 SP - 377 EP - 384 UR - http://dx.doi.org/10.1136/jech.52.6.377 ER - TY - BOOK LB - 72. AU - Chang, SM AU - Matchar, DB AU - Smetana, GW AU - Umscheid, CA AU - Gray, R AU - Torchia, MM TI - Methods Guide for Medical Test Reviews CY - Rockville, MD PB - AHRQ PY - 2012 UR - www.effectivehealthcare.ahrq.gov/ehc/products/246/558/Methods-Guide-for-Medical-Test-Reviews_Full-Guide_20120530.pdf Y2 - 11 March 2015 ER - TY - JOUR LB - 73. AU - Vande Casteele, N AU - Ferrante, M AU - Van Assche, G AU - Ballet, V AU - Compernolle, G AU - Van Steen, K TI - Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease J2 - Gastroenterology PY - 2015 VL - 148 SP - 1320 EP - 1329.e3 UR - http://dx.doi.org/10.1053/j.gastro.2015.02.031 ER - TY - JOUR LB - 74. AU - Guyot, P AU - Ades, A AU - Ouwens, M AU - Welton, N TI - Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves J2 - BMC Med Res Methodol PY - 2012 VL - 12 SP - 9 UR - http://dx.doi.org/10.1186/1471-2288-12-9 ER - TY - JOUR LB - 75. AU - Harbord, R AU - Whiting, P TI - metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression J2 - Stata J PY - 2009 VL - 9 SP - 211 EP - 229 ER - TY - JOUR LB - 76. AU - Harris, RJ AU - Bradburn, MJ AU - Deeks, JJ AU - Harbord, R AU - Altman, DG AU - Sterne, JAC TI - Metan: fixed- and random-effects meta-analysis J2 - Stata J PY - 2008 VL - 8 SP - 3 EP - 28 ER - TY - JOUR LB - 77. AU - Baert, F AU - Drobne, D AU - Gils, A AU - Vande Casteele, N AU - Hauenstein, S AU - Singh, S TI - Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy J2 - Clin Gastroenterol Hepatol PY - 2014 VL - 12 SP - 1474 EP - 81.e2 UR - http://dx.doi.org/10.1016/j.cgh.2014.01.033 ER - TY - JOUR LB - 78. AU - Ben-Bassat, O AU - Romanova, A AU - Iacono, A AU - Irwin, SP AU - Greenberg, GR TI - Association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn’s disease J2 - Gastroenterology PY - 2013 VL - 144 SP - S-775 UR - http://dx.doi.org/10.1016/S0016-5085(13)62866-8 ER - TY - JOUR LB - 79. AU - Ben-Horin, S AU - Yavzori, M AU - Katz, L AU - Kopylov, U AU - Picard, O AU - Fudim, E TI - The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful J2 - Gut PY - 2011 VL - 60 SP - 41 EP - 48 UR - http://dx.doi.org/10.1136/gut.2009.201533 ER - TY - JOUR LB - 80. AU - Ben-Horin, S AU - Mazor, Y AU - Yanai, H AU - Ron, Y AU - Kopylov, U AU - Yavzori, M TI - The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD J2 - Aliment Pharmacol Ther PY - 2012 VL - 35 SP - 714 EP - 722 UR - http://dx.doi.org/10.1111/j.1365-2036.2012.04997.x ER - TY - JOUR LB - 81. AU - Bodini, G AU - Savarino, V AU - Dulbecco, P AU - Baldissarro, I AU - Savarino, E TI - ELISA vs. HMSA: a comparison between two different methods for the evaluation of adalimumab serum concentration and anti-adalimumab antibodies preliminary data J2 - J Crohns Colitis PY - 2014 VL - 8 SP - S278 UR - http://dx.doi.org/10.1016/S1873-9946(14)60625-5 ER - TY - JOUR LB - 82. AU - Bortlik, M AU - Duricova, D AU - Malickova, K AU - Machkova, N AU - Bouzkova, E AU - Hrdlicka, L TI - Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease J2 - J Crohns Colitis PY - 2013 VL - 7 SP - 736 EP - 743 UR - http://dx.doi.org/10.1016/j.crohns.2012.10.019 ER - TY - JOUR LB - 83. AU - Candon, S AU - Mosca, A AU - Ruemmele, F AU - Goulet, O AU - Chatenoud, L AU - Cezard, JP TI - Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease J2 - Clin Immunol PY - 2006 VL - 118 SP - 11 EP - 19 UR - http://dx.doi.org/10.1016/j.clim.2005.07.010 ER - TY - JOUR LB - 84. AU - Chiu, YL AU - Rubin, DT AU - Vermeire, S AU - Louis, E AU - Robinson, AM AU - Lomax, KG TI - Serum adalimumab concentration and clinical remission in patients with Crohn’s disease J2 - Inflamm Bowel Dis PY - 2013 VL - 19 SP - 1112 EP - 1122 UR - http://dx.doi.org/10.1097/MIB.0b013e3182813242 ER - TY - JOUR LB - 85. AU - Cornillie, F AU - Hanauer, SB AU - Diamond, RH AU - Wang, J AU - Tang, KL AU - Xu, Z TI - Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial J2 - Gut PY - 2014 VL - 63 SP - 1721 EP - 1727 UR - http://dx.doi.org/10.1136/gutjnl-2012-304094 ER - TY - JOUR LB - 86. AU - Corstjens, PL AU - Fidder, HH AU - Wiesmeijer, KC AU - de Dood, CJ AU - Rispens, T AU - Wolbink, GJ TI - A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study J2 - Anal Bioanal Chem PY - 2013 VL - 405 SP - 7367 EP - 7375 UR - http://dx.doi.org/10.1007/s00216-013-7154-0 ER - TY - JOUR LB - 87. AU - Daperno, M AU - Frigerio, F AU - Guiotto, C AU - Germano, L AU - Ercole, E AU - Arico, S TI - Evaluation of the diagnostic performance of two commercially available tests for infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) titration in inflammatory bowel disease (IBD) J2 - J Crohns Colitis PY - 2013 VL - 7 SP - S213 EP - S214 UR - http://dx.doi.org/10.1016/S1873-9946(13)60529-2 ER - TY - JOUR LB - 88. AU - Dauer, RM AU - Yarur, AJ AU - Abreu, MT TI - Infliximab re-induction outcomes after a failure to treatment J2 - Gastroenterol PY - 2013 VL - 144 SP - S-430 UR - http://dx.doi.org/10.1016/S0016-5085(13)61583-8 ER - TY - JOUR LB - 89. AU - Egea-Pujol, L AU - Reddy, R AU - Patel, S AU - Christie, R AU - Salbato, J AU - Shah, S TI - Homogenous mobility shift assay (HMSA) overcomes the limitations of ELISA and ECLIA assays for monitoring infliximab (IFX), adalimumab (ADA), and associated anti-drug antibodies in serum J2 - Am J Gastroenterol PY - 2013 VL - 108 SP - S548 ER - TY - JOUR LB - 90. AU - Eser, A AU - Primas, C AU - Hauenstein, S AU - Lockton, S AU - Singh, S AU - Reinisch, W TI - Comparison of early measurement of infliximab and antibodies-to-infliximab serum levels with standard trough analysis J2 - Gastroenterology PY - 2013 VL - 144 SP - S-779 UR - http://dx.doi.org/10.1016/S0016-5085(13)62880-2 ER - TY - JOUR LB - 91. AU - Eser, A AU - Primas, C AU - Haunstein, S AU - Lockton, S AU - Wang, S AU - Singh, S TI - Detection of anti infliximab antibodies in patients with inflammatory bowel disease (IBD) in the presence of infliximab by homogeneous liquid phase anti infliximab mobility shift assay J2 - J Crohns Colitis PY - 2013 VL - 7 SP - S231 EP - S232 UR - http://dx.doi.org/10.1016/S1873-9946(13)60572-3 ER - TY - JOUR LB - 92. AU - Farrell, RJ AU - Alsahli, M AU - Jeen, YT AU - Falchuk, KR AU - Peppercorn, MA AU - Michetti, P TI - Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial J2 - Gastroenterology PY - 2003 VL - 124 SP - 917 EP - 924 UR - http://dx.doi.org/10.1053/gast.2003.50145 ER - TY - JOUR LB - 93. AU - Feagan, BG AU - Singh, S AU - Lockton, S AU - Hauenstein, S AU - Ohrmund, L AU - Croner, LJ TI - Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn’s disease (CD) J2 - Gastroenterology PY - 2012 VL - 142 SP - S-114 UR - http://dx.doi.org/10.1016/S0016-5085(12)60430-2 ER - TY - JOUR LB - 94. AU - Frederiksen, MT AU - Ainsworth, MA AU - Brynskov, J AU - Thomsen, OO AU - Bendtzen, K AU - Steenholdt, C TI - Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD J2 - Inflamm Bowel Dis PY - 2014 VL - 20 SP - 1714 EP - 1721 UR - http://dx.doi.org/10.1097/MIB.0000000000000138 ER - TY - JOUR LB - 95. AU - Goldberg, R AU - Beswick, L AU - Van Langenberg, D AU - Sally, B AU - Rosella, O AU - Gibson, P TI - Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions J2 - J Crohns Colitis PY - 2014 VL - 8 SP - S223 UR - http://dx.doi.org/10.1016/S1873-9946(14)60498-0 ER - TY - JOUR LB - 96. AU - Greathead, L AU - Kelleher, P AU - Steel, A TI - Development and validation of ELISA to measure serum anti TNFa levels J2 - J Crohns Colitis PY - 2014 VL - 8 SP - S97 EP - S98 UR - http://dx.doi.org/10.1016/S1873-9946(14)60208-7 ER - TY - JOUR LB - 97. AU - Hauenstein, S AU - Ohrmund, L AU - Salbato, J AU - Reddy, R AU - McCowen, K AU - Monk, P TI - Comparison of homogeneous mobility shift assay and solid phase elisa for the measurement of drug and anti-drug antibody (ADA) levels in serum from patients treated with anti-TNF biologics J2 - Gastroenterology PY - 2012 VL - 142 SP - S-538 UR - http://dx.doi.org/10.1016/S0016-5085(12)62067-8 ER - TY - JOUR LB - 98. AU - Hibi, T AU - Sakuraba, A AU - Watanabe, M AU - Motoya, S AU - Ito, H AU - Sato, N TI - C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease J2 - J Gastroenterol PY - 2014 VL - 49 SP - 254 EP - 262 UR - http://dx.doi.org/10.1007/s00535-013-0807-0 ER - TY - JOUR LB - 99. AU - Imaeda, H AU - Andoh, A AU - Fujiyama, Y TI - Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease J2 - J Gastroenterol PY - 2012 VL - 47 SP - 136 EP - 143 UR - http://dx.doi.org/10.1007/s00535-011-0474-y ER - TY - JOUR LB - 100. AU - Imaeda, H AU - Takahashi, K AU - Fujimoto, T AU - Bamba, S AU - Tsujikawa, T AU - Sasaki, M TI - Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease J2 - J Gastroenterol PY - 2014 VL - 49 SP - 100 EP - 109 UR - http://dx.doi.org/10.1007/s00535-013-0803-4 ER - TY - JOUR LB - 101. AU - Imaeda, H AU - Bamba, S AU - Takahashi, K AU - Fujimoto, T AU - Ban, H AU - Tsujikawa, T TI - Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment J2 - J Gastroenterol PY - 2014 VL - 49 SP - 674 EP - 682 UR - http://dx.doi.org/10.1007/s00535-013-0829-7 ER - TY - JOUR LB - 102. AU - Kong, JY AU - Bundell, CS AU - Pawlik, J AU - Hollingsworth, PN AU - Forbes, GM TI - Trough serum infliximab level, anti-infliximab antibody status and response to infliximab maintenance treatment in inflammatory bowel disease (IBD) J2 - J Gastroenterol Hepatol PY - 2011 VL - 26 SP - 59 EP - 60 ER - TY - JOUR LB - 103. AU - Kopylov, U AU - Mazor, Y AU - Yavzori, M AU - Fudim, E AU - Katz, L AU - Coscas, D TI - Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies J2 - Inflamm Bowel Dis PY - 2012 VL - 18 SP - 1628 EP - 1633 UR - http://dx.doi.org/10.1002/ibd.21919 ER - TY - JOUR LB - 104. AU - Levesque, BG AU - Greenberg, GR AU - Zou, G AU - Sandborn, WJ AU - Singh, S AU - Hauenstein, S TI - A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn’s disease J2 - Aliment Pharmacol Ther PY - 2014 VL - 39 SP - 1126 EP - 1135 UR - http://dx.doi.org/10.1111/apt.12733 ER - TY - JOUR LB - 105. AU - Marits, P AU - Landucci, L AU - Sundin, U AU - Davidsdottir, L AU - Nilsson, J AU - Befrits, R TI - Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment J2 - J Crohns Colitis PY - 2014 VL - 8 SP - 881 EP - 889 UR - http://dx.doi.org/10.1016/j.crohns.2014.01.009 ER - TY - JOUR LB - 106. AU - Marzo, M AU - Armuzzi, A AU - Felice, C AU - Pugliese, D AU - Andrisani, G AU - Tolusso, B TI - Role of trough levels and antibodies to infliximab in the evaluation of loss of response and infusion reactions to infliximab therapy in inflammatory bowel disease J2 - Dig Liver Dis PY - 2014 VL - 46 SP - S77 UR - http://dx.doi.org/10.1016/S1590-8658(14)60224-3 ER - TY - JOUR LB - 107. AU - Mazor, Y AU - Kopylov, U AU - Hur, DB AU - Almog, R AU - Waterman, M AU - Ben-Horin, S TI - Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn’s disease patients J2 - Gastroenterology PY - 2013 VL - 144 SP - S-778 UR - http://dx.doi.org/10.1016/S0016-5085(13)62874-7 ER - TY - JOUR LB - 108. AU - Mazor, Y AU - Almog, R AU - Kopylov, U AU - Ben Hur, D AU - Blatt, A AU - Dahan, A TI - Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease J2 - Aliment Pharmacol Ther PY - 2014 VL - 40 SP - 620 EP - 628 UR - http://dx.doi.org/10.1111/apt.12869 ER - TY - JOUR LB - 109. AU - McTigue, M AU - Sandborn, W AU - Levesque, B AU - Patel, D TI - Clinical utility of next generation infliximab and antibodies to infliximab assay J2 - Am J Gastroenterol PY - 2013 VL - 108 SP - S527 ER - TY - JOUR LB - 110. AU - Nagore, D AU - Ruiz Del Agua, A AU - Pascual, J AU - Llinares-Tello, F AU - Herreros, B AU - Martinez, A TI - Therapeutic cut-off of infliximab in patients with inflammatory bowel diseases J2 - Gut PY - 2015 VL - 64 SP - A99 UR - http://dx.doi.org/10.1136/gutjnl-2015-309861.202 ER - TY - JOUR LB - 111. AU - Nanda, KS AU - Cheifetz, AS AU - Moss, AC TI - Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis J2 - Am J Gastroenterol PY - 2013 VL - 108 SP - 40 EP - 47 UR - http://dx.doi.org/10.1038/ajg.2012.363 ER - TY - JOUR LB - 112. AU - Pallagi-Kunstar, E AU - Farkas, K AU - Szepes, Z AU - Nagy, F AU - Szucs, M AU - Kui, R TI - Utility of serum TNF-alpha, infliximab trough level, and antibody titers in inflammatory bowel disease J2 - World J Gastroenterol PY - 2014 VL - 20 SP - 5031 EP - 5035 UR - http://dx.doi.org/10.3748/wjg.v20.i17.5031 ER - TY - JOUR LB - 113. AU - Paul, S AU - Tedesco, ED AU - Marotte, H AU - Phelip, JM AU - Genin, C AU - Roblin, X TI - Interest of the dosage of serum concentration of infliximab and antibodies anti infliximab in the therapeutic response under infliximab in IBD J2 - Gastroenterology PY - 2012 VL - 142 SP - S354 UR - http://dx.doi.org/10.1016/S0016-5085(12)61332-8 ER - TY - JOUR LB - 114. AU - Paul, S AU - Moreau, AC AU - Del Tedesco, E AU - Rinaudo, M AU - Phelip, JM AU - Genin, C TI - Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis J2 - Inflamm Bowel Dis PY - 2014 VL - 20 SP - 1288 EP - 1295 UR - http://dx.doi.org/10.1097/MIB.0000000000000037 ER - TY - JOUR LB - 115. AU - Roblin, X AU - Marotte, H AU - Rinaudo, M AU - Del Tedesco, E AU - Moreau, A AU - Phelip, JM TI - Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases J2 - Clin Gastroenterol Hepatol PY - 2014 VL - 12 SP - 80 EP - 4.e2 UR - http://dx.doi.org/10.1016/j.cgh.2013.07.010 ER - TY - JOUR LB - 116. AU - Ruiz-Arguello, B AU - del Agua, AR AU - Torres, N AU - Monasterio, A AU - Martinez, A AU - Nagore, D TI - Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels J2 - Clin Chem Lab Med PY - 2013 VL - 51 SP - e287 EP - e289 UR - http://dx.doi.org/10.1515/cclm-2013-0461 ER - TY - JOUR LB - 117. AU - Schatz, SB AU - Prell, C AU - Freudenberg, F AU - Hajji, M AU - Bufler, P AU - Koletzko, S TI - PA-G-0035 Comparison of different tests for determination of infliximab levels and antibodies against infliximab in pediatric IBD patients. The 46th Annual Meeting of The European Society of Paediatric Gastroenterology, Hepatology and Nutrition, London, 8–11 May 2013 J2 - J Pediatr Gastroenterol Nutr PY - 2013 VL - 56 SP - 19 ER - TY - JOUR LB - 118. AU - Semmler, J AU - Pilch, A AU - Armbruster, F AU - Dignass, A AU - Stein, J TI - Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease J2 - Clin Chem Lab Med PY - 2013 VL - 51 SP - eA27 EP - eA28 ER - TY - JOUR LB - 119. AU - Singh, N AU - Rosenthal, CJ AU - Melmed, GY AU - Mirocha, J AU - Farrior, S AU - Callejas, S TI - Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease J2 - Inflamm Bowel Dis PY - 2014 VL - 20 SP - 1708 EP - 1713 UR - http://dx.doi.org/10.1097/MIB.0000000000000137 ER - TY - JOUR LB - 120. AU - Steenholdt, C AU - Bendtzen, K AU - Brynskov, J AU - Thomsen, OO AU - Ainsworth, MA TI - Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease J2 - Scand J Gastroenterol PY - 2011 VL - 46 SP - 310 EP - 318 UR - http://dx.doi.org/10.3109/00365521.2010.536254 ER - TY - JOUR LB - 121. AU - Steenholdt, C AU - Ainsworth, MA AU - Tovey, M AU - Klausen, TW AU - Thomsen, OO AU - Brynskov, J TI - Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease J2 - Ther Drug Monit PY - 2013 VL - 35 SP - 530 EP - 538 UR - http://dx.doi.org/10.1097/FTD.0b013e31828d23c3 ER - TY - JOUR LB - 122. AU - Steenholdt, C AU - Bendtzen, K AU - Brynskov, J AU - Thomsen, OO AU - Ainsworth, MA TI - Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post hoc analysis of a randomized controlled trial J2 - Am J Gastroenterol PY - 2014 VL - 109 SP - 1055 EP - 1064 UR - http://dx.doi.org/10.1038/ajg.2014.106 ER - TY - JOUR LB - 123. AU - Steenholdt, C AU - Brynskov, J AU - Thomsen, OO AU - Munck, LK AU - Fallingborg, J AU - Christensen, LA TI - Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial J2 - Gut PY - 2014 VL - 63 SP - 919 EP - 927 UR - http://dx.doi.org/10.1136/gutjnl-2013-305279 ER - TY - JOUR LB - 124. AU - Steenholdt, C AU - Brynskov, J AU - Thomsen OØ AU - Munck, LK AU - Fallingborg, J AU - Christensen, LA TI - Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn’s disease patients failing infliximab J2 - Dig Dis Sci PY - 2015 VL - 60 SP - 2762 EP - 2770 UR - http://dx.doi.org/10.1007/s10620-015-3581-4 ER - TY - JOUR LB - 125. AU - Ungar, B AU - Anafy, A AU - Kopylov, U AU - Ron, Y AU - Yanai, H AU - Dotan, I TI - The clinical and immunological significance of low level of infliximab in the absence of anti-infliximab antibodies in patients with IBD J2 - Gastroenterology PY - 2014 VL - 146 SP - S-245 UR - http://dx.doi.org/10.1016/S0016-5085(14)60862-3 ER - TY - JOUR LB - 126. AU - Vande Casteele, N AU - Gils, A AU - Singh, S AU - Ohrmund, L AU - Hauenstein, S AU - Rutgeerts, P TI - Antibody response to infliximab and its impact on pharmacokinetics can be transient J2 - Am J Gastroenterol PY - 2013 VL - 108 SP - 962 EP - 971 UR - http://dx.doi.org/10.1038/ajg.2013.12 ER - TY - JOUR LB - 127. AU - Vande Casteele, N AU - Peeters, M AU - Compernolle, G AU - Ferrante, M AU - Van Assche, GA AU - Vermeire, S TI - TNF-responsive cellular based assay reveals neutralizing capacity of anti-adalimumab antibodies in Crohn’s disease and ulcerative colitis patients J2 - Gastroenterology PY - 2014 VL - 146 SP - S-242 UR - http://dx.doi.org/10.1016/S0016-5085(14)60852-0 ER - TY - JOUR LB - 128. AU - Vaughn, BP AU - Martinez-Vazquez, M AU - Patwardhan, VR AU - Moss, AC AU - Sandborn, WJ AU - Cheifetz, AS TI - Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study J2 - Inflamm Bowel Dis PY - 2014 VL - 20 SP - 1996 EP - 2003 UR - http://dx.doi.org/10.1097/MIB.0000000000000156 ER - TY - JOUR LB - 129. AU - Wang, SL AU - Ohrmund, L AU - Singh, S TI - Measurement of human anti-chimeric antibodies (HACA) and infliximab levels in patient serum using a novel homogeneous assay J2 - Gastroenterology PY - 2010 VL - 138 SP - S684 EP - S685 UR - http://dx.doi.org/10.1016/s0016-5085(10)63147-2 ER - TY - JOUR LB - 130. AU - Wang, SL AU - Ohrmund, L AU - Hauenstein, S AU - Salbato, J AU - Reddy, R AU - Monk, P TI - Evaluation of a novel homogeneous mobility shift assay for the measurement of human antibodies-to-infliximab and infliximab levels in patient serum J2 - Am J Gastroenterol PY - 2011 VL - 106 SP - S475 EP - S476 ER - TY - JOUR LB - 131. AU - Wang, SL AU - Ohrmund, L AU - Hauenstein, S AU - Salbato, J AU - Reddy, R AU - Monk, P TI - Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum J2 - J Immunol Methods PY - 2012 VL - 382 SP - 177 EP - 188 UR - http://dx.doi.org/10.1016/j.jim.2012.06.002 ER - TY - JOUR LB - 132. AU - Ward, MG AU - Kariyawasam, VC AU - Mogan, SB AU - Blaker, PA AU - Patel, KP AU - Pantelidou, M TI - Clinical utility of measuring adalimumab trough levels and antibodies to adalimumab in patients with inflammatory bowel diseases J2 - J Gastroenterol Hepatol PY - 2013 VL - 28 SP - 100 EP - 101 ER - TY - JOUR LB - 133. AU - West, RL AU - Zelinkova, Z AU - Wolbink, GJ AU - Kuipers, EJ AU - Stokkers, PC AU - van der Woude, CJ TI - Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease J2 - Aliment Pharmacol Ther PY - 2008 VL - 28 SP - 1122 EP - 1126 UR - http://dx.doi.org/10.1111/j.1365-2036.2008.03828.x ER - TY - JOUR LB - 134. AU - Yanai, H AU - Mlynarsky, L AU - Ron, Y AU - Ben Yehoyada, M AU - Yeshuron, D AU - Santo, EM TI - The questionable value of infliximab trough levels during prolonged maintenance therapy J2 - Gastroenterology PY - 2012 VL - 142 SP - S788 EP - S789 UR - http://dx.doi.org/10.1016/S0016-5085(12)63061-3 ER - TY - JOUR LB - 135. AU - Yarur, AJ AU - Deshpande, AR AU - Sussman, DA AU - Hauenstein, S AU - Lockton, S AU - Barkin, JS TI - TU1147 serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease J2 - Gastroenterology PY - 2013 VL - 144 SP - S774 EP - S775 UR - http://dx.doi.org/10.1016/S0016-5085(13)62863-2 ER - TY - JOUR LB - 136. AU - Rispens, T AU - van der Kleij, D TI - Reply to Ruiz-Arguello et al.: comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels J2 - Clin Chem Lab Med PY - 2013 VL - 51 SP - e291 EP - e292 UR - http://dx.doi.org/10.1515/cclm-2013-0570 ER - TY - JOUR LB - 137. AU - Garces, S AU - Demengeot, J AU - Benito-Garcia, E TI - Clinical impact of immunogenicity of infliximab, adalimumab and etanercept: a systematic review of the literature with a meta-analysis (SAT0479) J2 - Ann Rheum Dis PY - 2013 VL - 71 SP - 634 EP - 635 UR - http://dx.doi.org/10.1136/annrheumdis-2012-eular.3425 ER - TY - JOUR LB - 138. AU - Lichtenstein, GR TI - Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response J2 - Therap Adv Gastroenterol PY - 2013 VL - 6 SP - 269 EP - 293 UR - http://dx.doi.org/10.1177/1756283X13479826 ER - TY - JOUR LB - 139. AU - Yanai, H AU - Hanauer, SB TI - Assessing response and loss of response to biological therapies in IBD J2 - Am J Gastroenterol PY - 2011 VL - 106 SP - 685 EP - 698 UR - http://dx.doi.org/10.1038/ajg.2011.103 ER - TY - JOUR LB - 140. AU - Vande Casteele, N AU - Khanna, R AU - Levesque, BG AU - Stitt, L AU - Zou, GY AU - Singh, S TI - The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease J2 - Gut PY - 2014 VL - 64 SP - 1539 EP - 1545 UR - http://dx.doi.org/10.1136/gutjnl-2014-307883 ER - TY - BOOK LB - 141. AU - Higgins, JPT AU - Green, S TI - Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 PB - The Cochrane Collaboration PY - 2011 UR - www.cochrane-handbook.org Y2 - 15 January 2015 ER - TY - JOUR LB - 142. AU - Seow, CH AU - Newman, A AU - Irwin, SP AU - Steinhart, AH AU - Silverberg, MS AU - Greenberg, GR TI - Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis J2 - Gut PY - 2010 VL - 59 SP - 49 EP - 54 UR - http://dx.doi.org/10.1136/gut.2009.183095 ER - TY - BOOK LB - 143. AU - Pepe, NS TI - The Statistical Evaluation of Medical Tests for Classification and Prediction CY - New York, NY PB - Oxford University Press PY - 2003 ER - TY - JOUR LB - 144. AU - Harbord, RM AU - Deeks, JJ AU - Egger, M AU - Whiting, P AU - Sterne, JA TI - A unification of models for meta-analysis of diagnostic accuracy studies J2 - Biostatistics PY - 2007 VL - 8 SP - 239 EP - 251 UR - http://dx.doi.org/10.1093/biostatistics/kxl004 ER - TY - JOUR LB - 145. AU - Rutgeerts, P AU - Sandborn, WJ AU - Feagan, BG AU - Reinisch, W AU - Olson, A AU - Johanns, J TI - Infliximab for induction and maintenance therapy for ulcerative colitis J2 - N Engl J Med PY - 2005 VL - 353 SP - 2462 EP - 2476 UR - http://dx.doi.org/10.1056/NEJMoa050516 ER - TY - JOUR LB - 146. AU - Sands, BE AU - Anderson, FH AU - Bernstein, CN AU - Chey, WY AU - Feagan, BG AU - Fedorak, RN TI - Infliximab maintenance therapy for fistulizing Crohn’s disease J2 - N Engl J Med PY - 2004 VL - 350 SP - 876 EP - 885 UR - http://dx.doi.org/10.1056/NEJMoa030815 ER - TY - JOUR LB - 147. AU - Miele, E AU - Markowitz, JE AU - Mamula, P AU - Baldassano, RN TI - Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab J2 - J Pediatr Gastroenterol Nutr PY - 2004 VL - 38 SP - 502 EP - 508 UR - http://dx.doi.org/10.1097/00005176-200405000-00008 ER - TY - JOUR LB - 148. AU - Steenholdt, C AU - Svenson, M AU - Bendtzen, K AU - Thomsen, O AU - Brynskov, J AU - Ainsworth, MA TI - Can measurements of anti-infliximab antibodies predict acute severe infusion reactions to infliximab? J2 - Gastroenterology PY - 2011 VL - 140 SP - S774 ER - TY - JOUR LB - 149. AU - Philips, Z AU - Ginnelly, L AU - Sculpher, M AU - Claxton, K AU - Golder, S AU - Riemsma, R TI - Review of guidelines for good practice in decision-analytic modelling in health technology assessment J2 - Health Technol Assess PY - 2004 VL - 8 IS - 36 UR - http://dx.doi.org/10.3310/hta8360 ER - TY - JOUR LB - 150. AU - Silverstein, MD AU - Loftus, EV AU - Sandborn, WJ AU - Tremaine, WJ AU - Feagan, BG AU - Nietert, PJ TI - Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort J2 - Gastroenterology PY - 1999 VL - 117 SP - 49 EP - 57 UR - http://dx.doi.org/10.1016/S0016-5085(99)70549-4 ER - TY - BOOK LB - 151. AU - Joint Formulary Committee TI - British National Formulary ET - 53 ed. CY - London PB - BMJ Group and Pharmaceutical Press PY - 2007 ER - TY - BOOK LB - 152. AU - Joint Formulary Committee TI - British National Formulary ET - 55 ed. CY - London PB - BMJ Group and Pharmaceutical Press PY - 2008 ER - TY - BOOK LB - 153. AU - Department of Health TI - NHS Reference Costs 2005 to 2006 CY - London PB - Department of Health PY - 2006 ER - TY - JOUR LB - 154. AU - Blackhouse, G AU - Assasi, N AU - Xie, F AU - Marshall, J AU - Irvine, EJ AU - Gaebel, K TI - Canadian cost–utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn’s disease J2 - J Crohns Colitis PY - 2012 VL - 6 SP - 77 EP - 85 UR - http://dx.doi.org/10.1016/j.crohns.2011.07.007 ER - TY - JOUR LB - 155. AU - Bodger, K AU - Kikuchi, T AU - Hughes, D TI - Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data J2 - Aliment Pharmacol Ther PY - 2009 VL - 30 SP - 265 EP - 274 UR - http://dx.doi.org/10.1111/j.1365-2036.2009.04033.x ER - TY - JOUR LB - 156. AU - Kaplan, GG AU - Hur, C AU - Korzenik, J AU - Sands, BE TI - Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis J2 - Aliment Pharmacol Ther PY - 2007 VL - 26 SP - 1509 EP - 1520 UR - http://dx.doi.org/10.1111/j.1365-2036.2007.03548.x ER - TY - JOUR LB - 157. AU - Velayos, FS AU - Kahn, JG AU - Sandborn, WJ AU - Feagan, BG TI - A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn’s disease who lose responsiveness to infliximab J2 - Clin Gastroenterol Hepatol PY - 2013 VL - 11 SP - 654 EP - 666 UR - http://dx.doi.org/10.1016/j.cgh.2012.12.035 ER - TY - JOUR LB - 158. AU - Husereau, D AU - Drummond, M AU - Petrou, S AU - Carswell, C AU - Moher, D AU - Greenberg, D TI - Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement J2 - Int J Technol Assess Health Care PY - 2013 VL - 29 SP - 117 EP - 122 UR - http://dx.doi.org/10.1017/S0266462313000160 ER - TY - JOUR LB - 159. AU - Juillerat, P AU - Sokol, H AU - Froehlich, F AU - Yajnik, V AU - Beaugerie, L AU - Lucci, M TI - Factors associated with durable response to infliximab in Crohn’s disease 5 years and beyond: a multicenter international cohort J2 - Inflamm Bowel Dis PY - 2015 VL - 21 SP - 60 EP - 70 UR - http://dx.doi.org/10.1097/MIB.0000000000000225 ER - TY - JOUR LB - 160. AU - van der Have, M AU - van der Aalst, KS AU - Kaptein, AA AU - Leenders, M AU - Siersema, PD AU - Oldenburg, B TI - Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis J2 - J Crohns Colitis PY - 2014 VL - 8 SP - 93 EP - 106 UR - http://dx.doi.org/10.1016/j.crohns.2013.04.007 ER - TY - JOUR LB - 161. AU - Ma, C AU - Huang, V AU - Fedorak, DK AU - Kroeker, KI AU - Dieleman, LA AU - Halloran, BP TI - Crohn’s disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study J2 - J Crohns Colitis PY - 2014 VL - 8 SP - 1454 EP - 1463 UR - http://dx.doi.org/10.1016/j.crohns.2014.05.007 ER - TY - JOUR LB - 162. AU - Sandborn, WJ AU - Rutgeerts, P AU - Enns, R AU - Hanauer, SB AU - Colombel, JF AU - Panaccione, R TI - Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial J2 - Ann Intern Med PY - 2007 VL - 146 SP - 829 EP - 838 UR - http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00159 ER - TY - JOUR LB - 163. AU - Nguyen, GC AU - Nugent, Z AU - Shaw, S AU - Bernstein, CN TI - Outcomes of patients with Crohn’s disease improved from 1988 to 2008 and were associated with increased specialist care J2 - Gastroenterology PY - 2011 VL - 141 SP - 90 EP - 97 UR - http://dx.doi.org/10.1053/j.gastro.2011.03.050 ER - TY - JOUR LB - 164. AU - Gordon, M AU - Taylor, K AU - Akobeng, AK AU - Thomas, AG TI - Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn’s disease J2 - Cochrane Database Syst Rev PY - 2014 VL - 8 SP - CD010233 UR - http://dx.doi.org/10.1002/14651858.cd010233.pub2 ER - TY - JOUR LB - 165. AU - Rutgeerts, P AU - D’Haens, G AU - Targan, S AU - Vasiliauskas, E AU - Hanauer, SB AU - Present, DH TI - Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease J2 - Gastroenterology PY - 1999 VL - 117 SP - 761 EP - 769 UR - http://dx.doi.org/10.1016/S0016-5085(99)70332-X ER - TY - BOOK LB - 166. AU - Joint Formulary Committee TI - British National Formulary CY - 66 ed. London PB - BMJ Group and Pharmaceutical Press PY - 2013 ER - TY - BOOK LB - 167. AU - Department of Health TI - NHS Reference Costs 2013 to 2014 CY - London PB - Department of Health PY - 2014 UR - www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014 Y2 - 24 March 2015 ER - TY - JOUR LB - 168. AU - Marchetti, M AU - Liberato, NL TI - Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses J2 - Expert Rev Pharmacoecon Outcomes Res PY - 2014 VL - 14 SP - 815 EP - 824 UR - http://dx.doi.org/10.1586/14737167.2014.957682 ER - TY - GEN LB - 169. AU - Office for National Statistics TI - National Life Tables, United Kingdom, 1980–82 to 2011–13 PY - 2014 UR - www.ons.gov.uk/ons/search/index.html?newquery=National+Life+Tables%2C+United+Kingdom%2C+1980-82+to+2011-13 Y2 - 31 March 2015 ER - TY - BOOK LB - 170. AU - Curtis, L TI - Unit Costs of Health and Social Care 2014 CY - Canterbury PB - Personal Social Services Research Unit, University of Kent PY - 2014 UR - www.pssru.ac.uk/project-pages/unit-costs/2014/ Y2 - 24 March 2015 ER - TY - JOUR LB - 171. AU - Saito, S AU - Shimizu, U AU - Zhang, N AU - Yokoyama, J AU - Watanabe, M AU - Terajima, K J2 - Health (NY) PY - 2014 VL - 6 SP - 107 EP - 114 UR - http://dx.doi.org/10.4236/health.2014.61017 ER - TY - JOUR LB - 172. AU - Rai, T AU - Navaneethan, U AU - Dalal, D AU - Lashner, B AU - Shen, B TI - Clinical implications of measuring infliximab levels and human anti-chimeric antibodies in patients with inflammatory bowel disease J2 - Am J Gastroenterol PY - 2012 VL - 107 SP - S634 ER - TY - JOUR LB - 173. AU - Armbruster, S AU - Ally, M AU - Maydonovitch, C AU - Betteridge, J AU - Veerappan, G TI - The use of human anti-chimeric antibody (HACA) and infliximab levels in the management of inflammatory bowel disease J2 - Am J Gastroenterol PY - 2012 VL - 107 SP - S641 ER - TY - JOUR LB - 174. AU - Vande Casteele, N AU - Drake, K AU - Hauenstein, S AU - Levesque, BG AU - Singh, S AU - Sandborn, W TI - Infliximab and antibody to infliximab concentrations in 7,613 patients shows indication for testing, association with loss of response and provides new insights into binding characteristics of anti-drug antibodies J2 - Gastroenterology PY - 2014 VL - 146 SP - S-242 UR - http://dx.doi.org/10.1016/S0016-5085(14)60853-2 ER - TY - JOUR LB - 175. AU - Wolf, DC AU - Lockton, S AU - Hauenstein, S AU - Carroll, S AU - Singh, S AU - Chuang, E TI - A multi-center observational study in community gastroenterology practices evaluating the clinical usage of testing for serum levels of infliximab and antibodies to infliximab J2 - Gastroenterology PY - 2013 VL - 144 SP - S-423 UR - http://dx.doi.org/10.1016/S0016-5085(13)61559-0 ER - TY - JOUR LB - 176. AU - Turon, J AU - Langseder, A AU - Irizarry, R AU - Ahuja, K AU - Rosh, JR TI - Clinical outcome of pediatric IBD patients after measurement of infliximab drug and anti-drug antibody levels J2 - Gastroenterology PY - 2013 VL - 144 SP - S531 UR - http://dx.doi.org/10.1016/S0016-5085(13)61975-7 ER - TY - JOUR LB - 177. AU - Turvill, J TI - Mapping of Crohn’s disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy J2 - Frontline Gastroenterol PY - 2014 VL - 5 SP - 167 EP - 175 UR - http://dx.doi.org/10.1136/flgastro-2014-100441 ER - TY - BOOK LB - 178. AU - NICE TI - Infliximab, Adalimumab and Golimumab for Treating Moderately to Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. NICE technology appraisal guidance [TA329] CY - London PB - NICE PY - 2015 ER - TY - JOUR LB - 179. AU - Bar-yoseph, H AU - Chowers, Y AU - Ben-Horin, S AU - Waterman, M TI - Infliximab is more immunogenic and reaches lower trough levels in ulcerative colitis patients compared to Crohn’s disease patients J2 - Gastroenterology PY - 2013 VL - 144 SP - S-780 UR - http://dx.doi.org/10.1016/S0016-5085(13)62883-8 ER - TY - JOUR LB - 180. AU - D’Haens, GR AU - Vermiere, S AU - Lambrecht, G AU - Baert, FJ AU - Bassuyt, P AU - Nachury, M TI - 692 Drug-level based dosing versus symptom-based dose adaptation in patients with crohn's disease: a prospective, randomized multicenter study (TAILORIX) J2 - Gastroenterology PY - 2016 VL - 150 SP - S143 UR - http://dx.doi.org/10.1016/S0016-5085(16)30583-2 ER - TY - BOOK LB - 181. AU - D’Haens, G AU - Vermeire, S AU - Lambrecht, G AU - Baert, F AU - Bossuyt, P AU - Nachury, M AU - European Crohn’s and Colitis Organisation TI - OP029 Drug-Concentration Versus Symptom-Driven Dose Adaptation of Infliximab in Patients with Active Crohn’s Disease: A Prospective, Randomised, Multicentre Trial (Tailorix) PY - 2016 UR - www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2016/item/op029-drug-concentration-versus-symptom-driven-dose-adaptation-of-infliximab-in-patients-with-active-crohnix2019is-disease-a-prospective-randomised-multicentre-trial-tailorix.html Y2 - 29 September 2016 ER - TY - JOUR LB - 182. AU - Nagore, D AU - Ruiz Del Agua, A AU - Pascual, J AU - Llinares-Tello, F AU - Herreros, B AU - Martinez, A TI - TU1325 therapeutic cut-off of infliximab in patients with inflammatory bowel diseases J2 - Gastroenterology PY - 2015 VL - 148 SP - S-860 UR - http://dx.doi.org/10.1016/S0016-5085(15)32913-9 ER - TY - JOUR LB - 183. AU - Vester-Andersen, MK AU - Vind, I AU - Prosberg, MV AU - Bengtsson, BG AU - Blixt, T AU - Munkholm, P TI - Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003–2011 – a Danish population-based cohort study J2 - J Crohns Colitis PY - 2014 VL - 8 SP - 1675 EP - 1683 UR - http://dx.doi.org/10.1016/j.crohns.2014.07.010 ER - TY - JOUR LB - 184. AU - Ramadas, AV AU - Gunesh, S AU - Thomas, GA AU - Williams, GT AU - Hawthorne, AB TI - Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates J2 - Gut PY - 2010 VL - 59 SP - 1200 EP - 1206 UR - http://dx.doi.org/10.1136/gut.2009.202101 ER - TY - JOUR LB - 185. AU - Armuzzi, A AU - Felice, C AU - Papa, A AU - Marzo, M AU - Pugliese, D AU - Andrisani, G TI - Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn’s disease: an open-label pilot study J2 - J Crohns Colitis PY - 2013 VL - 7 SP - e623 EP - e629 UR - http://dx.doi.org/10.1016/j.crohns.2013.04.020 ER -